Advertisement


Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Advertisement